Leaflet Thickening and Immobility in Evolut Low Risk

Leaflet thickening and immobility caused by thrombosis have been reported for both surgical and transcatheter bioprostheses.

Engrosamiento e inmovilidad de las valvas en el Evolut Low Risk

This phenomenon is diagnosed through hypoattenuation, thickening, and lack of motion, as observed through computed tomography (CT) imaging.

The incidence and, especially, the clinical implications of this phenomenon remain unclear, but they are of great interest, particularly in a low-risk population for whom device durability may be affected.

This work is an Evolut Low Risk sub-study that includes patients who were not receiving anticoagulant agents and who were assessed through CT at 30 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery.

The primary endpoint was the incidence of leaflet thickening at 30 days and 1 year. Imaging scans were analyzed by an independent committee using standardized definitions. Secondary endpoints included reduced leaflet motion, mean aortic gradient, and clinical events.


Read also: Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves.


At 30 days, the rate of thickening was 17.3% for transcatheter valves and 16.5% for surgically-implanted valves. Reduced motion was observed in 14.6% and 14.3% of patients, respectively.

After 1 year, its rate doubled in both patient groups. The rate of thickening in transcatheter valves was 30.9%, compared with 28.4% for surgically-implanted valves, and the rate of reduced motion was 31%, compared with 27%, respectively.

Gradients were not influenced by the presence or severity of thickening and reduced motion at any time during follow-up.


Read also: Meta-Analysis of Large TAVR Studies on Low-Risk: Evidence is Consistent.


The rates for both phenomena observed through CT were similar with supra-annular, self-expanding transcatheter, and surgical bioprostheses.

Conclusion

The presence of CT imaging abnormalities in aortic bioprostheses was frequent, but it did not affect any hemodynamic parameters, at least at 1 year. A longer follow-up is required (particularly in this low-risk population) to determine whether thickening could impact prosthesis durability.

Original Title: Leaflet Thickening or Immobility Following Aortic Valve Replacement: Results from the Evolut Low Risk Sub-study.

Reference: Philipp Blanke et al. Journal of the American College of Cardiology. Journal Pre-proof. https://doi.org/10.1016/j.jacc.2020.03.022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...